BridgeMD
New treatment option for HEPATITIS C (HCV)
Official title Implementing Low-Barrier HCV Treatment in a Jail Setting
ClinicalTrials.gov ID: NCT06953479
What this study is testing
What is Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]?
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for hepatitis c (hcv).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting trial.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Incarcerated individual at RIDOC
- Age ≥ 18 years
- Awaiting trial (i.e., not sentenced)
- English speaking
- Diagnosis of active HCV (HCV RNA \>1000 IU/mL within 90 days prior to study entry)
You likely can't join if
- Cirrhosis (FIB-4 Score \>3.25 within 90 days prior to study entry and/or clinical signs of cirrhosis)
- Positive for Hepatitis B surface antigen
- Actively pregnant or breastfeeding
- Known allergy/sensitivity to study drug components
- Acute or serious illness requiring hospitalization at enrollment
- Documented severe persistent mental illness (SPMI) by RIDOC
See the full eligibility criteria
- Incarcerated individual at RIDOC
- Age ≥ 18 years
- Awaiting trial (i.e., not sentenced)
- English speaking
- Diagnosis of active HCV (HCV RNA \>1000 IU/mL within 90 days prior to study entry)
- Treatment-naïve for current HCV infection
- No cirrhosis (FIB-4 Score \<3.25 within 90 days prior to study entry)
- Self-report of injection drug use
- Ability and willingness to be contacted after jail release
- Verbal commitment to continue medication after discharge
- Desire to receive Sofosbuvir/Velpatasvir (Epclusa)
- Cirrhosis (FIB-4 Score \>3.25 within 90 days prior to study entry and/or clinical signs of cirrhosis)
- Positive for Hepatitis B surface antigen
- Actively pregnant or breastfeeding
- Known allergy/sensitivity to study drug components
- Acute or serious illness requiring hospitalization at enrollment
- Documented severe persistent mental illness (SPMI) by RIDOC
- Any clinical history of hepatic decompensation (e.g., ascites, SBP, HE, HRS, variceal bleeding)
- HIV-positive with active or acute AIDS-defining opportunistic infection within 90 days
The study team makes the final eligibility decision.
Where it's taking place
- Cranston, Rhode Island, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cranston, Rhode Island, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.